NVS - DiaMedica: Proven Stroke Drug In Asia Headed To The U.S.

• DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial.
• Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20+ years in Asia to treat stroke/kidney disease.
• A near-term Asian strategic partner could provide a $5-$20 million upfront payment with a potential of $50+ million in milestone payments for DM199 distribution rights.
• Insider buying of 110K+ shares in Q3-2021 is a very positive signal. The average price target from 5 Wall Street analysts is $22, or 5x the current price.
• A recent capital raise eliminates concern over any future dilution. No capital should be needed until mid-2023 after the pivotal stroke study results are released and the kidney indications.

For further details see: